Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Medix Biochemica unleashes $5 million expansion to secure future of IVD supply chain

The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer